Literature DB >> 32568190

Assessing the Utility of Language and Voice Biomarkers to Predict Cognitive Impairment in the Framingham Heart Study Cognitive Aging Cohort Data.

Jason A Thomas1, Hannah A Burkhardt1, Safina Chaudhry1, Anthony D Ngo1, Saransh Sharma1, Larry Zhang1, Rhoda Au2, Reza Hosseini Ghomi1.   

Abstract

BACKGROUND: There is a need for fast, accessible, low-cost, and accurate diagnostic methods for early detection of cognitive decline. Dementia diagnoses are usually made years after symptom onset, missing a window of opportunity for early intervention.
OBJECTIVE: To evaluate the use of recorded voice features as proxies for cognitive function by using neuropsychological test measures and existing dementia diagnoses.
METHODS: This study analyzed 170 audio recordings, transcripts, and paired neuropsychological test results from 135 participants selected from the Framingham Heart Study (FHS), which includes 97 recordings of cognitively normal participants and 73 recordings of cognitively impaired participants. Acoustic and linguistic features of the voice samples were correlated with cognitive performance measures to verify their association.
RESULTS: Language and voice features, when combined with demographic variables, performed with an AUC of 0.942 (95% CI 0.929-0.983) in predicting cognitive status. Features with good predictive power included the acoustic features mean spectral slope in the 500-1500 Hz band, variation in the F2 bandwidth, and variation in the Mel-Frequency Cepstral Coefficient (MFCC) 1; the demographic features employment, education, and age; and the text features of number of words, number of compound words, number of unique nouns, and number of proper names.
CONCLUSION: Several linguistic and acoustic biomarkers show correlations and predictive power with regard to neuropsychological testing results and cognitive impairment diagnoses, including dementia. This initial study paves the way for a follow-up comprehensive study incorporating the entire FHS cohort.

Entities:  

Keywords:  Alzheimer’s disease; artificial intelligence; biomarkers; cognitive dysfunction; data collection; dementia; early diagnosis; language; neuropsychological tests; voice

Mesh:

Substances:

Year:  2020        PMID: 32568190     DOI: 10.3233/JAD-190783

Source DB:  PubMed          Journal:  J Alzheimers Dis        ISSN: 1387-2877            Impact factor:   4.472


  6 in total

1.  Voice biomarkers as indicators of cognitive changes in middle and later adulthood.

Authors:  Elizabeth Mahon; Margie E Lachman
Journal:  Neurobiol Aging       Date:  2022-07-01       Impact factor: 5.133

2.  Health Professionals' Experience Using an Azure Voice-Bot to Examine Cognitive Impairment (WAY2AGE).

Authors:  Carmen Moret-Tatay; Hernán Mario Radawski; Cecilia Guariglia
Journal:  Healthcare (Basel)       Date:  2022-04-22

3.  Detection of dementia on voice recordings using deep learning: a Framingham Heart Study.

Authors:  Chonghua Xue; Cody Karjadi; Ioannis Ch Paschalidis; Rhoda Au; Vijaya B Kolachalama
Journal:  Alzheimers Res Ther       Date:  2021-08-31       Impact factor: 8.823

4.  Using Digital Tools to Advance Alzheimer's Drug Trials During a Pandemic: The EU/US CTAD Task Force.

Authors:  J Kaye; P Aisen; R Amariglio; R Au; C Ballard; M Carrillo; H Fillit; T Iwatsubo; G Jimenez-Maggiora; S Lovestone; F Natanegara; K Papp; M E Soto; M Weiner; B Vellas
Journal:  J Prev Alzheimers Dis       Date:  2021

5.  Neuropsychological test validation of speech markers of cognitive impairment in the Framingham Cognitive Aging Cohort.

Authors:  Larry Zhang; Anthony Ngo; Jason A Thomas; Hannah A Burkhardt; Carolyn M Parsey; Rhoda Au; Reza Hosseini Ghomi
Journal:  Explor Med       Date:  2021-06-30

6.  Aducanumab: Appropriate Use Recommendations.

Authors:  J Cummings; P Aisen; L G Apostolova; A Atri; S Salloway; M Weiner
Journal:  J Prev Alzheimers Dis       Date:  2021
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.